Molecular docking to understand the metabolic behavior of GNF-351 by CYP3A4 and its potential drug-drug interaction with ketoconazole

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 40, Issue 2, 2015, Pages 235-238

  Liu, Tao ^a   Qian, Ge ^b   Wang, WenTing ^c   Zhang, YanGuo ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b ZHENGZHOU CHILDREN S HOSPITAL   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Drug drug interaction; GNF 351; Ketoconazole

Indexed keywords

ANTIINFLAMMATORY AGENT; CYTOCHROME P450 3A4; GNF 351; KETOCONAZOLE; UNCLASSIFIED DRUG; CYTOCHROME P450 3A; INDOLE DERIVATIVE; N-(2-(3H-INDOL-3-YL)ETHYL)-9-ISOPROPYL-2-(5-METHYL-3-PYRIDYL)PURIN-6-AMINE; PURINE DERIVATIVE;

ARTICLE; CRYSTAL STRUCTURE; DRUG ABSORPTION; DRUG BINDING; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; MOLECULAR DOCKING; PROCESS OPTIMIZATION; PROTEIN DOMAIN; PROTEIN STRUCTURE; X RAY CRYSTALLOGRAPHY; CHEMISTRY; DRUG INTERACTION; HUMAN; METABOLISM;

CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HUMANS; INDOLES; KETOCONAZOLE; MOLECULAR DOCKING SIMULATION; PURINES;

EID: 84938738716     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-014-0201-1     Document Type: Article

References (17)

1. An G, Liu W, Katz DA, Marek G, Awni W, Dutta S (2013) Effect of ketoconazole on the pharmacokinetics of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 and its two active metabolites in healthy volunteers: population analysis of data from a drug-drug interaction study. Drug Metab Dispos 41(5):1035-1045
2. Barouki R, Coumoul X, Fernandez-Salguero PM (2007) The aryl hydrocarbon receptor, more than a xenobiotic-interacting protein. FEBS Lett 581:3608-3615
3. Bren U, Oostenbrink C (2012) Cytochrome P450 3A4 inhibition by ketoconazole: tackling the problem of ligand cooperativity using molecular dynamics simulations and free-energy calculations. J Chem Inf Model 52(6):1573-1582
4. Cheng J, Shah YM, Ma X, Pang X, Tanaka T, Kodama T et al (2010) Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J Pharmacol Exp Ther 335(1):32-41
5. Dowty ME, Lin J, Ryder TF, Wang W, Walker GS, Vaz A, Chan GL, Krishnaswami S, Prakash C (2014) The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a Janus kinase inhibitor, in humans. Drug Metab Dispos 42(4):759-773
6. Fang ZZ, Krausz KW, Li F, Cheng J, Tanaka N, Gonzalez FJ (2012) Metabolic map and bioactivation of the anti-tumor drug noscapine. Br J Pharmacol 167(6):1271-1286
7. Fang ZZ, Krausz KW, Nagaoka K, Tanaka N, Gowda K, Amin SG et al (2014) In vivo application of the pure aryl hydrocarbon receptor antagonist GNF-351 is limited to the gastrointestinal track. Br J Pharmacol 171(7):1735-1746
8. Guner OF, Bowen JP (2013) Pharmacophore modeling for ADME. Curr Top Med Chem 13(11):1327-1342
9. Han B, Mao J, Chien JY, Hall SD (2013) Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole. Drug Metab Dispos 41(7):1329-1338
10. Jin XL, Tang SH, Fang ZZ, Qu YQ, Liang R, Gao ZM, Tang B, Sun DG, Li M, Yang L, Wang LM (2011) Reversible and time-dependent inhibition of CYP3A4-mediated nifedipine oxidation by noscapine. Lat Am J Pharm 30(9):1854-1857
11. Liu K, Li F, Lu J, Liu S, Dorko K, Xie W, Ma X (2014) Bedaquiline metabolism: enzymes and novel metabolites. Drug Metab Dispos. doi: 10.1124/dmd.113.056119
12. Ma X, Shah YM, Guo GL, Wang T, Krausz KW, Idle JR et al (2007) Rifaximin is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther 322(1):391-398
13. Morcos PN, Moreira SA, Brennan BJ, Blotner S, Shulman NS, Smith PF (2013) Influence of chronic hepatitis C infection on cytochrome P450 3A4 activity using midazolam as an in vivo probe substrate. Eur J Clin Pharmacol 69(10):1777-1784
14. Sager JE, Lutz JD, Foti RS, Davis C, Kunze KL, Isoherranen N (2014) Fluoxetine and norfluoxetine mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19 and CYP3A4. Clin Pharmacol Ther. doi: 10.1038/clpt.2014.50
15. Shrestha S, Jha AK, Pathak DT, Kharel CB, Basukala SM (2013) Ketoconazole or clotrimazole solution wash as a prophylaxis in management and prevention of fungal infection: a comparative study. Nepal Med Coll J 15(1):31-33
16. Veldhoen M, Hirota K, Christensen J, O'Garra A, Stockinger B (2009) Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J Exp Med 206:43-49
17. Yan JH, Meyers D, Lee Z, Danis K, Neelakantham S, Majumdar T, Rebello S, Sunkara G, Chen J (2014) Pharmacokinetic and pharmacodynamic drug-drug interaction assessment between pradigastat and digoxin or warfarin. J Clin Pharmacol. doi: 10.1002/jcph.285